MX2008014279A - Derivados de 17-oximacbecina y su uso en el tratamiento de cancer y/o malignidades de celula b. - Google Patents

Derivados de 17-oximacbecina y su uso en el tratamiento de cancer y/o malignidades de celula b.

Info

Publication number
MX2008014279A
MX2008014279A MX2008014279A MX2008014279A MX2008014279A MX 2008014279 A MX2008014279 A MX 2008014279A MX 2008014279 A MX2008014279 A MX 2008014279A MX 2008014279 A MX2008014279 A MX 2008014279A MX 2008014279 A MX2008014279 A MX 2008014279A
Authority
MX
Mexico
Prior art keywords
cancer
diseases
treatment
cell malignancies
represent
Prior art date
Application number
MX2008014279A
Other languages
English (en)
Inventor
Ming-Qiang Zhang
Sabine Gaisser
Christine Martin
Nigel Coates
Original Assignee
Biotica Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd
Publication of MX2008014279A publication Critical patent/MX2008014279A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a análogos de 17-oximacbecina de conformidad con la fórmula (IA) o (IB) a continuación, (ver fórmula (IA) o (IB)) o una sal farmacéuticamente aceptable del mismo, en donde: R1 representa H, OH u OCH3; R2 representa H o CH3, R3 representa H o CONH2, R4 y R5 ya sea ambos representan H o juntos representan un enlace (esto es C4 hasta C5 es un enlace doble); y R6 representa H u OH; y R7 representa H o CH3, que son útiles, por ejemplo en el tratamiento de cáncer, malignidades de célula B, paludismo, infección por hongos, enfermedades del sistema nervioso central y enfermedades neurodegenerativas, enfermedades dependientes de angiogénesis, enfermedades autoinmunitarias y/o como un pretratamiento profiláctico para el cáncer. La presente invención también proporciona métodos para la producción de estos compuestos y su uso en medicina, en particular en el tratamiento y/o profilaxis de cáncer o malignidades de célula B.
MX2008014279A 2006-05-09 2007-05-09 Derivados de 17-oximacbecina y su uso en el tratamiento de cancer y/o malignidades de celula b. MX2008014279A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0609117.7A GB0609117D0 (en) 2006-05-09 2006-05-09 Novel compounds
PCT/EP2007/054473 WO2007128827A1 (en) 2006-05-09 2007-05-09 17-oxymacbecin derivatives and their use in the treatment of cancer and/or b-cell malignancies

Publications (1)

Publication Number Publication Date
MX2008014279A true MX2008014279A (es) 2008-11-26

Family

ID=36637122

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008014279A MX2008014279A (es) 2006-05-09 2007-05-09 Derivados de 17-oximacbecina y su uso en el tratamiento de cancer y/o malignidades de celula b.

Country Status (11)

Country Link
US (1) US20100068203A1 (es)
EP (1) EP1940798A1 (es)
JP (1) JP2009536934A (es)
KR (1) KR20090005377A (es)
CN (1) CN101437802A (es)
AU (1) AU2007247119A1 (es)
BR (1) BRPI0711092A2 (es)
CA (1) CA2651557A1 (es)
GB (1) GB0609117D0 (es)
MX (1) MX2008014279A (es)
WO (1) WO2007128827A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007319015A1 (en) * 2006-11-09 2008-05-15 Biotica Technology Limited 18, 21-didesoxymacbecin derivatives for the treatment of cancer
US9967590B2 (en) 2008-04-10 2018-05-08 Qualcomm Incorporated Rate-distortion defined interpolation for video coding based on fixed filter or adaptive filter
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CN110999828A (zh) * 2019-12-19 2020-04-14 上海海洋大学 改变鱼类体色分布模式的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2146668A1 (en) * 1992-10-14 1994-04-28 Luke Whitesell Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
JPH11504924A (ja) * 1995-05-02 1999-05-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ベンゾキノン類アンサマイシンによる熱耐性の誘導

Also Published As

Publication number Publication date
WO2007128827A1 (en) 2007-11-15
EP1940798A1 (en) 2008-07-09
GB0609117D0 (en) 2006-06-21
AU2007247119A1 (en) 2007-11-15
US20100068203A1 (en) 2010-03-18
JP2009536934A (ja) 2009-10-22
KR20090005377A (ko) 2009-01-13
CN101437802A (zh) 2009-05-20
WO2007128827A8 (en) 2008-01-03
CA2651557A1 (en) 2007-11-15
BRPI0711092A2 (pt) 2011-08-23

Similar Documents

Publication Publication Date Title
DE60329001D1 (en) 8-hydroxychinolinderivate
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
TW200728307A (en) Novel spirochromanone derivatives
SI1585739T1 (sl) Substituirani arilciklopropilacetamidi kot aktivatorji glukokinaze
EP1732384A4 (en) NOVEL SYNTHETIC C-GLYCOLIPIDES, THEIR SYNTHESIS AND USE FOR THE TREATMENT OF INFECTIONS, CANCER AND AUTOIMMUNE DISEASES
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
GEP20115199B (en) Phosphatidylinositol 3-kinase inhibitors and their use
MX2008014279A (es) Derivados de 17-oximacbecina y su uso en el tratamiento de cancer y/o malignidades de celula b.
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
PL2001633T3 (pl) Głowica skrawająca i złączka
MX2010004435A (es) Compuestos espiro y uso farmaceutico de los mismos.
WO2005051946A3 (en) Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
NZ592880A (en) Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
MY141559A (en) Triazole derivatives as tachykinin receptor antagonists
HK1140755A1 (en) Morphinan compounds
HK1138262A1 (en) Novel phosphodiesterase inhibitors
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
MY133527A (en) Isoquinoline derivatives
MX2019008331A (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
WO2007128829A3 (en) 18,21-didesoxymacbecin derivatives for the treatment of cancer
DE60114640D1 (en) Antithrombosemittel
TW200638929A (en) Tricyclic cytoprotective compounds
MY136938A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
MXPA05008906A (es) Estra-1,3,5-(10)-trien-3-il-sulfamatos 2-sustituidos, con actividad antitumoral.